4.4 Review

What are the core recommendations for rheumatoid arthritis care? Systematic review of clinical practice guidelines

Journal

CLINICAL RHEUMATOLOGY
Volume 42, Issue 9, Pages 2267-2278

Publisher

SPRINGER LONDON LTD
DOI: 10.1007/s10067-023-06654-0

Keywords

Evidence-based care; Rheumatoid arthritis; Practice guidelines; Evidence-based medicine; Systematic review

Categories

Ask authors/readers for more resources

This study conducted a systematic review to evaluate the quality of clinical practice guidelines for rheumatoid arthritis (RA) management and provided a synthesis of high-quality recommendations. The review identified 13 eligible guidelines that highlighted the importance of both non-pharmacological and pharmacological care for RA management. This synthesis offers clear evidence-based guidance for healthcare providers.
Systematic review to evaluate the quality of the clinical practice guidelines (CPG) for rheumatoid arthritis (RA) management and to provide a synthesis of high-quality CPG recommendations, highlighting areas of consistency, and inconsistency. Electronic searches of five databases and four online guideline repositories were performed. RA management CPGs were eligible for inclusion if they were written in English and published between January 2015 and February 2022; focused on adults = 18 years of age; met the criteria of a CPG as defined by the Institute of Medicine; and were rated as high quality on the Appraisal of Guidelines for Research and Evaluation II instrument. RA CPGs were excluded if they required additional payment to access; only addressed recommendations for the system/organization of care and did not include interventional management recommendations; and/or included other arthritic conditions. Of 27 CPGs identified, 13 CPGs met eligibility criteria and were included. Non-pharmacological care should include patient education, patient-centered care, shared decision-making, exercise, orthoses, and a multi-disciplinary approach to care. Pharmacological care should include conventional synthetic disease modifying anti-rheumatic drugs (DMARDs), with methotrexate as the first-line choice. If monotherapy conventional synthetic DMARDs fail to achieve a treatment target, this should be followed by combination therapy conventional synthetic DMARDs (leflunomide, sulfasalazine, hydroxychloroquine), biologic DMARDS and targeted synthetic DMARDS. Management should also include monitoring, pre-treatment investigations and vaccinations, and screening for tuberculosis and hepatitis. Surgical care should be recommended if non-surgical care fails. This synthesis offers clear guidance of evidence-based RA care to healthcare providers.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available